Details of Drug-Drug Interaction
| Drug General Information (ID: DDITW45BCF) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Pegfilgrastim | Drug Info | Interferon alfa-2a, Recombinant | Drug Info | |||||
| Drug Type | Small molecule | Interferons | |||||||
| Therapeutic Class | Immunomodulatory Agents | Interferons | |||||||
| Mechanism of Pegfilgrastim-Interferon alfa-2a, Recombinant Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Attenuated pharmacological effects (Unspecific) Click to Show/Hide Mechanism Graph | |||||||||
| Drug Name | Pegfilgrastim | Interferon alfa-2a, Recombinant | |||||||
| Mechanism | Hematopoietic growth factors | Reduce therapeutic efficacy of hematopoietic growth factors | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Pharmacodynamics | ||||||||
| Factor Description | Reduced pharmacological effects leading to insufficient efficacy and/or treatment failure. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Because of the potential sensitivity of rapidly dividing myeloid cells to cancer chemotherapy, the manufacturer recommends that pegfilgrastim not be given from 14 days before until 24 hours after administration of antineoplastic agents. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA. | ||||||||||||||||||
| 2 | Product Information. Neulasta (pegfilgrastim). Amgen, Thousand Oaks, CA. | ||||||||||||||||||